Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

QL1706

Drug and asset intelligence for QL1706 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Recent signals(1)

ClinicalJune 26, 2026

SBRT Combined with QL1706 Shows Promise in Second-Line Hepatocellular Carcinoma Therapy

A clinical trial is underway to evaluate the efficacy and safety of SBRT plus QL1706 in patients with hepatocellular carcinoma after prior systemic therapy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

AstraZeneca — QL1706

Key milestones include patient enrollment completion and initial efficacy results based on the primary endpoint of objective response rate.

June 26, 2026 · N/A

Indications

Hepatocellular Carcinoma →

Therapeutic areas

Hepatocellular Carcinoma →

Oncology · Hepatocellular Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.